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Available online xxxxBackground: Chronic obstructive pulmonary disease (COPD) has been associated with atrial ﬁbrillation (AF).
More insight into the epidemiology and underlying mechanisms is required to optimize management.
Methods: The Rotterdam Study is a large, population-based cohort study with long-term follow-up. Time depen-
dent Cox proportional hazard models were constructed to study the effect of COPD on incident AF, adjusted for
age, sex and pack years of cigarette smoking, and additionally stratiﬁed according to exacerbation frequency, left
atrial size and baseline systemic inﬂammatory levels.
Results: 1369 of 10,943 subjects had COPD, of whom 804 developed AF. The AF incidence rate was 14 per 1000
person years in COPD and 8 per 1000 person years in subjects without COPD. The adjusted hazard ratio (HR)
for COPD subjects to develop AF as compared to subjects without COPDwas 1.28 (95%CI [1.04, 1.57]). COPD sub-
jectswith frequent exacerbations had a twofold increased AF risk (HR 1.99 [1.42, 2.79]) and COPD subjects with a
left atrial size ≥40 mm also had an elevated AF risk (HR 1.77 [1.07, 2.94]). COPD subjects with baseline systemic
inﬂammatory levels above the median had signiﬁcantly increased AF risks (hsCRP≥1.83 mg/L: HR 1.51 [1.13,
2.03] and IL6 ≥ 1.91 ng/L: HR 2.49 [1.18, 5.28]), whereas COPD subjects below the median had in both analyses
no signiﬁcantly increased AF risk.
Conclusions: COPD subjects had a 28% increased AF risk, which further increasedwith frequent exacerbations and
an enlarged left atrium. The risk was driven by COPD subjects having elevated systemic inﬂammatory levels.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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.09.0561. Introduction
Atrial ﬁbrillation (AF) is the most common sustained cardiac
arrhythmia worldwide, having an estimated prevalence of 3% in adults
aged ≥20 years, affecting 20.9 million men and 12.6 million women
worldwide in 2010 [1–3]. AF is associated with increased rates of coro-
nary artery disease, cerebrovascular accidents and other thromboem-
bolic events, chronic heart failure, low quality of life, reduced exercise
capacity and cognitive dysfunction [3–7]. Risk factors for AF include
increasing age, male sex, hypertension, diabetes mellitus, myocardial
infarction, valvular heart disease, heart failure, obstructive sleep
apnea, chronic kidney disease, hyperthyroidism, obesity, heavy alcohol
consumption and smoking [3–14]. Additionally, an enlarged left atrium
due to structural remodeling in response to oxidative stress and inﬂam-
mation, is a proven risk factor for developing AF [15].
Chronic obstructive pulmonary disease (COPD) is one of the most
common diseases worldwide characterized by progressive airﬂowthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2010, with a global prevalence of 11.7% and an overall prevalence in
men aged ≥30 years of 14.3% compared to 7.6% in women [18]. Exacer-
bations contribute to the overall severity in individual patients, since
they have a negative effect on quality of life, cause an accelerated
decline in lung function, and are associated with signiﬁcant mortality,
especially in hospitalized patients [19]. COPD is associated with many
co-morbidities and is considered an independent risk factor for cardio-
vascular morbidity and mortality [20–23]. Examining the potential as-
sociation between COPD and incident AF, and identifying vulnerable
patient groups can be useful for earlier detection of patients at risk for
AF, by increasing awareness on risk factors and risk patients for clinical
practice and by highlighting the opportunities for improved prevention
and treatment of cardiovascular morbidity and mortality in COPD
patients [24].
Previous studies have investigated the association between COPD
and AF, but these studies are often limited in design (e.g. cross-
sectional studies studying only the co-occurrence), sample size and
follow-up time [22,25]. An association between reduced lung function
and incident AF has been established longitudinally in the Copenhagen
Heart Study in 2003, but this study did not evaluate COPD exacerbations
or the effect of left atrial size on the association [22]. Identifying the ef-
fect of frequent COPD exacerbations and left atrial size on AF develop-
ment in COPD patients is however useful for identifying a subset of
patients at higher risk of incident AF. Furthermore, the role of systemic
inﬂammation in COPD as a potential underlying pathophysiological
mechanism of AF development has not been fully elucidated, but is im-
portant as it may improve therapeutic recommendations.
In this large prospective population-based study we aimed to deter-
mine the AF incidence in COPD subjects compared to subjects without
COPD, aswell as the effect of frequent COPD exacerbations and left atrial
size on the association. Finally, this is one of the ﬁrst studies with the
aim to investigate the role of underlying systemic inﬂammation in
COPD on AF development.
2. Methods
2.1. Setting
The Rotterdam Study is a prospective population-based cohort study in Rotterdam,
the Netherlands, consisting of 14,926 subjects [26,27]. It consists of three independent co-
horts, which are followed until present. Rotterdam Study I (RS-I) started with a baseline
visit between 1990 and 1993, enrolling 7983 subjects aged ≥55 years; RS-II started be-
tween 2000 and 2001, enrolling 3011 subjects aged ≥55 years; and RS-III started between
2006 and2007, enrolling 3932 subjects aged≥45 years. There is a continuous follow-up for
morbidity andmortality through linkage with digital medical records from general practi-
tioners (GP) in the study area, collection of letters of medical specialists, discharge reports
in case of hospitalization andmunicipal health authorities in Rotterdam. There are regular
examination cycles every 3 to 5 years at the study center during which multiple tests, in-
cluding spirometry and electrocardiography (ECG), are performed. Information on life-
style factors, such as smoking, is obtained through systematic interviews and
questionnaires. The Rotterdam Study has been approved by theMedical Ethics Committee
of the Erasmus MC and by the Ministry of Health, Welfare and Sport of the Netherlands,
implementing the “Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam
Study)”. All subjects provided written informed consent to participate in the study and to
obtain information from their treating physicians.
2.2. AF assessment
Threemethodswere used for the assessment of prevalent and incident AF. Firstly, 10 s
ECGs with 12 leads and stored digitally, were taken at baseline and during follow-up ex-
aminations [26,28]. All ECGs were analyzed by the Modular ECG Analysis System
(MEANS). To verify thediagnosis of AF, all ECGswith aMEANSdiagnosis of AF, atrialﬂutter
or any other rhythm disorder were independently reviewed by two research physicians
who were blinded to the MEANS diagnosis. In case of a persisting disagreement between
the coding physicians, a cardiologist made the ﬁnal diagnosis.
Secondly, additional medical information was obtained from the subject's GP. This in-
formation included investigations performed by the GP or by a physician in a hospital set-
ting. AF was included in case of diagnosis by a specialist or by the GP with ECG evidence.
Thirdly, the national registry of hospital discharge diagnoses was searched for the di-
agnosis of AF. AF was not included as a case if AF developed during the process of dying
while AF was not the cause of dying or if transient AF occurred during a hospitalization
for myocardial infarction or cardiac operative procedures.Please cite this article as: M. Grymonprez, et al., Chronic obstructive pulm
(2018), https://doi.org/10.1016/j.ijcard.2018.09.056The incident AF date was either determined by incidence date in medical records or,
when AF was ﬁrst diagnosed at the research center, the incident date was the mean be-
tween the conﬁrming ECG date and the last examination date within the Rotterdam
Study which showed no AF. Subjects with AF at baseline or with missing data regarding
AF were excluded.
2.3. COPD assessment
COPD was diagnosed by an obstructive spirometry at the research center, or, in ab-
sence of an interpretable spirometry at the research center, by a physician based on clinical
history, physical examination or spirometry performed outside the investigations of the
research center [27,29]. The diagnosis of COPD using spirometry at the study center was
deﬁned by the GOLD (Global Initiative for Chronic Obstructive Lung Disease) deﬁnition:
FEV1/FVC b0.7 based on pre-bronchodilator lung function testing which was available
from 2002 onwards [20]. Subjects with physician diagnosed asthma were excluded.
When the diagnosis of asthma or COPD was uncertain or overlapping, subjects were also
excluded [27,29].
The incidence date of COPDwas determined aswhichever date came ﬁrst: the date of
obstructive lung functionmeasurement at the research center, the date of COPD diagnosis
by a physician or the date of ﬁrst medication for obstructive lung disease. Subjects with
frequent exacerbationswere determined as subjects who had at least twomoderate or se-
vere exacerbations on average per year during the entire follow-up [30]. Moderate COPD
exacerbations were deﬁned as exacerbations treated with oral corticosteroids and/or an-
tibiotics, whereas a severe COPD exacerbationwas deﬁned as a COPDworsening requiring
hospitalization [31].
2.4. Assessment of systemic inﬂammation
Plasma interleukin 6 (IL6) and high-sensitivity C-reactive protein (hsCRP) levelswere
measured in RS-I during a stable state as previously described (33). IL6 plasma levelswere
measured in a 10% random subset who received venipuncture at the start of the study
(1990–1993) by application of minimal stasis with a 21-gauge butterﬂy needle tube
(Surﬂo winged infusion set, Terumo) (33). After nonfasting blood was collected in tubes
containing 0.129 mol/L sodium citrate at 4 °C, plasma was yielded after centrifugation
for 10 min at 3000 rpm and subsequently, platelet-free plasma was yielded by centrifuga-
tion for 10 min at 10000 rpm and immediately frozen in liquid nitrogen, and stored at
−80 °C (33). Using a commercially available ELISA (Quantikine HS IL6 kit from R&D
Systems Europe), IL6 levels were measured with an interassay coefﬁcient of variation
for IL6 of 8.7% (33).
2.5. Statistical analyses
For the descriptive statistics, median and interquartile range (IQR) are presented for
continuous variables, and number and percentage for categorical variables. A non-
parametric Mann-Whitney U test was performed to determine if continuous variables
were different between subjects with or without COPD, and a Chi-Square test was used
to determine signiﬁcant differences in categorical variables.
The association between COPD and incident AFwas evaluated using a time dependent
Cox proportional hazard model. The start of study follow-up was determined as either
(1) the date of study entry if the participant had prevalent COPD at baseline, (2) the
incidence date of COPD during follow-up, or (3) the date of study entry if the participant
did not have prevalent COPD at baseline and did not develop COPD during follow-up.
The last day of follow-up was determined as either (1) the incidence date of AF, (2) the
date of death or (3) December 31, 2010, whichever came ﬁrst. An additional time depen-
dent Cox proportional hazard model was used to examine the association between COPD
with or without frequent exacerbations and incident AF during the same follow-up. A
stratiﬁed subset analysiswas performed to explore the effect of left atrial size on the asso-
ciation between prevalent COPD at the date of echocardiography and incident AF. Left
atrial size (in mm) was measured on echocardiography between 2002 and 2011. The
start of study follow-up was the ﬁrst date of echocardiography. The last day of follow-up
was determined as previously stated.
Besides age (years) and sex, models were adjusted for the following covariates
according to the previous literature when changing the risk estimate by N10%: smoking
behavior (never, former, current smoker), pack years of cigarette smoking, alcohol use
(g/day), height (cm), weight (kg), BMI (kg/m2), total serum cholesterol (mmol/L),
diabetesmellitus, hypertension, systolic and diastolic bloodpressure (mmHg), acutemyo-
cardial infarction, coronary artery bypass grafting, percutaneous coronary intervention,
chronic heart failure and chronic kidney disease [3–10,29]. The information of the covari-
ates was obtained through interview, laboratory tests, medical ﬁles or physical examina-
tion during the ﬁrst visit of the study center at baseline [27]. Pack years of cigarette
smoking were computed as the duration of self-reported smoking in years multiplied by
the number of daily smoked cigarettes divided by 20 (1 pack). Blood pressure was mea-
sured in a sitting position at the right arm, taking the average of two consecutivemeasure-
ments. A subject had baseline hypertension if having a systolic and/or diastolic blood
pressure of ≥140 and/or ≥90mmHg or using antihypertensivemedication.Myocardial in-
farction was deﬁned using a combination of symptoms, ECG results and enzymemarkers.
Heart failure diagnosiswas determined in accordancewith the guidelines of the European
Society of Cardiology. The estimated glomerular ﬁltration rate (eGFR)was calculatedwith
the MDRD formula. Chronic kidney failure as a dichotomous variable was deﬁned as hav-
ing an eGFRofb60ml/min/1.73m2. Diabetesmellituswas deﬁned as either fasting glucoseonary disease and the development of atrial ﬁbrillation, Int J Cardiol
3M. Grymonprez et al. / International Journal of Cardiology xxx (xxxx) xxx–xxxN6.9mmol/l, non-fasting glucose N11.0mmol/l, the use of blood glucose loweringmedica-
tion, or a previous diagnosis of diabetesmellitus. SPSS statistics 22 (IBMCorp., Somers, NY,
USA) was used for the analyses.3. Results
After exclusion of subjects due to AF at baseline, missing AF data or
asthma, 10,943 subjects were included (Fig. 1). Table 1 demonstrates
the baseline characteristics of the study population. The 1369 subjects
with COPD were more frequently male, older and had smoked more
pack years. Myocardial infarction was signiﬁcantly more prevalent in
COPD subjects.
Regarding the association between COPD and incident AF, 131 of
1369 COPD developed AF during 9569 person years (PY) of follow-up
(incidence rate (IR) 13.7/1000 PY), whereas 673 of 9574 subjects
without COPD had incident AF during 89,673 PY of follow-up (IR 7.5/
1000 PY).(Fig. 2) Of the 131 COPD subjects who developed AF, 41
(31%) COPD subjects developed AF within eight weeks from the
start of an exacerbation, and 8 (20%) of those exacerbationswere severe
requiring hospitalization. The analysis for confounding variables besides
age and sex showed that only pack years of cigarette smoking had a
pronounced effect (N10%) on the association between COPD and
AF. The increased risk during follow-up for COPD subjects to
develop AF as compared to subjects without COPD was 1.28 (95%CI
[1.04, 1.57], p value 0.018) adjusted for age, sex and pack years of
cigarette smoking.
Regarding the effect of COPD exacerbations (Fig. 3), the adjusted HR
for COPD subjects with frequent exacerbations to develop AF as com-
pared to subjects without COPD was 1.99 (95%CI [1.42, 2.79], p value
b0.001) (Table 2). Stratiﬁed for sex, the adjusted risk of incident AF
was more pronounced in females with frequent exacerbations (HRFig. 1. Flowchart. AF, atrial ﬁbrillation; COPD
Please cite this article as: M. Grymonprez, et al., Chronic obstructive pulm
(2018), https://doi.org/10.1016/j.ijcard.2018.09.0562.46, 95%CI [1.48, 4.08], p value 0.001) than in males with frequent ex-
acerbations (HR 1.67, 95%CI [1.06, 2.63], p value 0.026), both compared
to subjects without COPD. When comparing the risk within COPD sub-
jects, the additional adjusted risk for having frequent exacerbations to
develop AF was 1.82 (95%CI [1.23, 2.69], p value 0.003).
Regarding the effect of left atrial size, the association between COPD
and incident AF has been explored in the subset of subjects with left
atrial echocardiographic measurement. 481 COPD subjects at date of
echocardiography (median left atrial size 39 mm, IQR 36–43 mm),
and 5374 subjects without COPD (median left atrial size 40 mm, IQR
36–43 mm) were followed within this analysis (p value 0.165). Median
age was 66.5 years (IQR 58.8–74.2) at start of follow-up, which was the
date of echocardiography. During 30,472 PY of follow-up, 172 subjects
developed AF. Stratiﬁed on left atrial size, the adjusted incident AF risk
was only signiﬁcantly higher for COPD subjects compared to subjects
without COPD in the stratum of subjects with a left atrial size ≥40 mm
(HR 1.77, 95%CI [1.07, 2.94], p value 0.027; vs HR 1.15, 95%CI
[0.50–2.62], p value 0.745, if left atrial size b40 mm).
Regarding the role of baseline systemic inﬂammatory levels, analy-
ses were stratiﬁed below or above the median hsCRP and IL6 level, re-
spectively. hsCRP was measured in 5545 of 5904 (94%) included RS-I
subjects. Table 3 demonstrates that COPD subjects with hsCRP ≥median
of 1.83 mg/L, had a 1.5 signiﬁcantly increased AF risk as compared to
subjects without COPD (HR 1.51 [1.13, 2.03], p value 0.005). The AF
risk in COPD subjects below the median hsCRP level was not signiﬁ-
cantly increased. Within the 10% random subset of the 5904 included
RS-I subjects with baseline plasma IL6 measurement (n = 599), COPD
subjects with IL6 ≥median of 1.91 ng/L, had a 2.5 signiﬁcantly increased
AF risk as compared to subjects without COPD (HR 2.49 [1.18, 5.28], p
value 0.017). The AF risk in COPD subjects below the median IL6 was
not increased., chronic obstructive pulmonary disease.
onary disease and the development of atrial ﬁbrillation, Int J Cardiol
Table 1
Baseline characteristics table.
Baseline characteristics of subjects with or without COPD
COPD No COPD p-value
n= 1369 n= 9574
Demographics
Male - no. (%) 757 (55.3) 3893 (40.7) b0.001
Age (IQR) – year 69.6 (62.3–76.2) 62.2 (57.7–71.4) b0.001
BMI (IQR) - kg/m2 25.8 (23.5–28.3) 26.4 (24.2–29.0) b0.001
Height (IQR) - cm 170.0 (163.0–176.5) 167.2 (161.0–174.8) b0.001
Weight (IQR) - kg 74.7 (66.9–83.6) 74.8 (66.2–84.1) 0.613
Pack years of cigarette smoking (IQR) 26.3 (7.7–44.0) 3.5 (0–22.0) b0.001
Smoking status b0.001
Never smoker - no. (%) 208 (15.5) 3503 (37.4)
Former smoker - no. (%) 578 (43.2) 4089 (43.6)
Current smoker - no. (%) 553 (41.3) 1785 (19.0)
Alcohol (IQR) - g/day 2.9 (0–7.1) 1.6 (0–7.1) 0.625
Sex-speciﬁc eGFR (IQR) - ml/min/1.73 m2 74.9 (66.2–85.5) 73.8 (64.9–83.7) 0.001
Cholesterol (IQR) - mmol/l 6.2 (5.4–7.0) 6.1 (5.3–6.9) 0.076
IL6 (IQR) – pg/ml 2.0 (1.4–3.4) 1.9 (1.2–3.0) 0.132
hsCRP (IQR) - mg/l 1.9 (0.9–3.8) 1.5 (0.6–3.1) b0.001
Systolic blood pressure (IQR) - mm Hg 136.0 (123.0–151.0) 136.0 (123.0–152.0) 0.372
Diastolic blood pressure (IQR) - mm Hg 76.0 (68.0–84.0) 77.0 (69.0–85.0) b0.001
Pulse pressure (IQR) - mm Hg 59.0 (49.0–71.0) 58.0 (47.0–71.0) 0.111
Comorbidities
Chronic kidney disease (b60 ml/min/1.73m2) - no. (%) 131 (12.0) 1201 (15.2) 0.005
Myocardial infarction - no. (%) 91 (6.7) 431 (4.5) 0.001
Coronary artery bypass graft - no. (%) 28 (2.1) 165 (1.8) 0.410
Percutaneous coronary intervention - no. (%) 16 (1.2) 123 (1.3) 0.707
Heart failure - no. (%) 30 (2.2) 143 (1.5) 0.054
Diabetes mellitus - no. (%) 128 (9.3) 903 (9.4) 0.923
(Treated) hypertension - no. (%) 639 (52.9) 4517 (53.8) 0.546
AF, atrial ﬁbrillation; BMI, body mass index; hsCRP, high-sensitivity C-reactive protein; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular ﬁltration rate;
IQR, interquartile range;
BMIwasmissing in 217, height in 210, weight in 207, pack years of cigarette smoking in 482, smoking status in 227, alcohol in 3081, eGFR in 1925, cholesterol in 218, IL6 in 10,524,
CRP in 602, systolic blood pressure in 126, diastolic blood pressure in 126, pulse pressure in 126, atrial size in 4542, chronic kidney disease in 1925, myocardial infarction in 54,
coronary artery bypass graft in 218, percutaneous coronary intervention in 218, heart failure in 36 and (treated) hypertension data in 1335 subjects.
Fig. 2.Kaplan–Meier plot of the proportion of participants free from atrial ﬁbrillation over the follow-up time indays. Blue line, subjectswithout COPD; red dotted line, subjectswith COPD.
(For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 3. Kaplan-Meier plot of the proportion of participants free from atrial ﬁbrillation over the follow-up time in days. Blue line, subjects without COPD; orange dotted line, subjects with
COPDwithout frequent exacerbations; red striped line, subjects with COPDwith frequent exacerbations (at least two per year). (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
Table 2
Hazard ratios for association between no COPD, COPD without (b2/y) and with frequent exacerbations (≥2/y), and incident AF.
Total n Events Median follow-up
time in years (IQR)
HR (95% CI) p-value
Crude model
No COPD 9574 673 9.1 (11.4) Reference
COPD without freq. ex. 1076 88 6.1 (6.8) 1.54 (1.24–1.93) b0.001
COPD with freq. ex. 290 43 5.3 (8.0) 2.87 (2.11–3.91) b0.001
Adjusted model⁎
No COPD 9153 630 9.1 (11.2) Reference
COPD without freq. ex. 1034 81 6.0 (6.8) 1.11 (0.87–1.40) 0.407
COPD with freq. ex. 271 37 5.2 (8.0) 1.99 (1.42–2.79) b0.001
AF, atrial ﬁbrillation; CI, Conﬁdence interval; COPD, chronic obstructive pulmonary disease; Freq. ex., frequent exacerbations; HR, Hazard Ratio; IQR, interquartile range.
⁎ Adjusted for age, sex and pack years of cigarette smoking.
Table 3
Hazard ratios for association between COPD and incident AF, stratiﬁed according to baseline systemic inﬂammatory levels.
Total n Events Median follow-up time
in years (IQR)
HR (95% CI)⁎ p-value
hsCRP b 1.83 mg/L
No COPD 2242 255 17.2 (9.0) Reference
COPD 353 37 7.6 (8.6) 1.04 (0.72–1.49) 0.852
hsCRP ≥ 1.83 mg/L
No COPD 2108 241 12.5 (11.9) Reference
COPD 426 62 7.6 (8.2) 1.51 (1.13–2.03) 0.005
IL6 b 1.91 ng/L
No COPD 239 29 17.8 (9.1) Reference
COPD 38 3 8.3 (10.1) 0.53 (0.14–1.97) 0.341
IL6 ≥ 1.91 ng/L
No COPD 231 33 10.9 (11.6) Reference
COPD 47 11 7.6 (6.0) 2.49 (1.18, 5.28) 0.017
AF, atrial ﬁbrillation; CI, Conﬁdence interval; COPD, chronic obstructive pulmonary disease; hsCRP, high-sensitivity C reactive protein; HR, Hazard Ratio; IL6, Interleukin 6;
IQR, interquartile range.
⁎ Adjusted for age, sex and pack years of cigarette smoking.
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In this large population-based cohort study, we demonstrate that
COPD subjects have an increased risk of developing AF, even after
adjusting for the relevant confounding variables. Importantly, only
COPD subjects with elevated hsCRP and IL6 plasma levels had a signiﬁ-
cantly increased risk, suggesting the potential role of systemic inﬂam-
mation on AF development present in a subset of COPD patients.
Increasing evidence supports the role of systemic inﬂammation, charac-
terized by elevation of various inﬂammatory mediators such as CRP, IL6
and tumor necrosis factorα, in the pathophysiology of AF development
and progression [32–35]. Likewise, COPD and its disease severity have
been associated with elevated levels of several inﬂammatory markers
including IL6 and CRP, potentially linking systemic inﬂammation to var-
ious extra-pulmonary complications of COPD such as cachexia, osteopo-
rosis, muscle wasting, diabetes mellitus and cardiovascular disease
[36–40]. The role of systemic inﬂammation might provide new thera-
peutic options for preventing the occurrence and recurrence of AF in
COPD, but potentially also a practical prognostic marker for incident
AF in COPD bymeasuring baseline IL6. Further research is needed to ex-
amine these therapeutic interventions such as statins, ACE-inhibitors
and corticosteroids, as well as new therapies speciﬁcally targeting IL6
in COPD.
Furthermore in terms of COPD severity, the risk was most pro-
nounced in COPD subjects with frequent exacerbations. Because COPD
exacerbations usually require medical assistance, such occasions pro-
vide ideal opportunities for detecting potential incident AF. Still, further
research is needed to investigate whether screening for AF in high risk
COPD patients provides an additional beneﬁt on clinical outcomes,
such as hospitalizations and survival. However, it is known that earlier
AF detection might facilitate faster therapeutic interventions, protect
against potential AF complications and slow down its progression
[4,22].
Moreover, COPD patients with an enlarged left atrium were signiﬁ-
cantly more at risk of developing AF. Atrial size has already been linked
to hyperuricemia and alcohol consumption in new-onset AF, but an as-
sociation between COPD and atrial enlargement as a potential interme-
diate phenotype along the causal pathway to AF development has not
been clearly investigated [41,42]. This could be used as an echocardio-
graphic parameter in predicting incident AF in COPD patients. Still, fur-
ther research is needed to investigate the clinical signiﬁcance of these
ﬁndings.
Our results that COPD subjects have a signiﬁcantly increased AF risk,
are in line with previous ﬁndings. For example, Buch et al. found an in-
verse relationship between FEV1% predicted and AF [22]. Chahal et al.
also found that reduced lung function as measured by FEV1 was signiﬁ-
cantly associated with incident AF [43]. Additionally, Konecny et al.
found that incident AF occurred signiﬁcantly more among COPD
subjects [25].
Postulated mechanisms as an explanation for the association be-
tween COPD and AF are multiple and can be differentiated in patho-
physiological mechanisms leading to right and/or left atrial changes. In
case of AF originating in the right atrium in COPD patients, the following
mechanisms are proposed: hypoxia, hypercapnia and acidosis due to
ventilation perfusionmismatching can lead to pulmonary hypertension
due to pulmonary arteriolar constriction, resulting in right ventricular
hypertrophy and diastolic dysfunction, which in turn can increase
right atrial diameter, transmural pressure and myocardial stretching
[22,23,44–47]. In acute exacerbations, impaired lung function, hyper-
capnia and increased pulmonary artery systolic pressure are proven to
be independent predictors of incident AF [47]. Moreover, acute exacer-
bations lead to increased levels of IL6, hsCRP, and ﬁbrinogen [48]. Since
up to a third of all AF onsets among COPD subjects were registered in
our study during the eight week period of a COPD exacerbation, COPD
subjects seemparticularly prone to developAF during this unstable con-
dition. These results are in linewith observations that COPD subjects arePlease cite this article as: M. Grymonprez, et al., Chronic obstructive pulm
(2018), https://doi.org/10.1016/j.ijcard.2018.09.056at the highest risk of developing an adverse cardiovascular event during
or shortly after an exacerbation [36,37,47]. Moreover, as recommended
by the GOLD guidelines, severe COPD exacerbations are treated with
high dose systemic corticosteroids, which have been associated with
an increased risk of incident AF [49], while low dose corticosteroids
had previously shown to prevent AF recurrence post cardioversion by
signiﬁcantly reducing CRP [50].
Besides inducing oxidative stress triggering ectopic ﬁring foci (often
originating in thewalls of pulmonary veins) and aggravating left ventri-
cle systolic dysfunction in the acute setting [51], COPD-related systemic
inﬂammation might also play a role in AF originating in the left atrium
in COPD patients by facilitating atrial structural remodeling on the
long-term [47]. Persistent systemic inﬂammation is not a constant fea-
ture of COPD, as described by Agusti et al., but when present for at
least one year, it is associated with worse outcomes after three years
of follow-up [37].Moreover, our resultswithin the subsetwith left atrial
sizemeasurement also indicate that COPD subjectswith an enlarged left
atrium, which may be the consequence of structural remodeling due to
systemic inﬂammation, may be particularly prone to develop AF. This
correlates with the ﬁndings of Psychari et al. who found that left atrial
diameter was positively related to CRP and IL6 [52].
Lastly, medication use, such as β-agonists, anticholinergic drugs,
methylxanthine agents and oral corticosteroids, has recently been pro-
posed as a potential pathophysiologicalmechanism for AF development
in COPD [22,23,44–47].
This study has many strength such as the population-based setting,
the large number of subjects, the long-term follow-up and the blinded
assessment of the determinant (COPD) and the outcome (AF). Still,
some limitations should be mentioned. First, the exact date of AF inci-
dence was difﬁcult to determine, even more because AF can be asymp-
tomatic and paroxysmal. Because subjects with known AF at start of
follow-up were excluded, latency might have underestimated this
amount of subjects. Furthermore, we could not distinguish between
paroxysmal and persistent AF, as our large population-based cohort de-
sign did not allow regular Holtermonitoring in all patients to determine
underlying paroxysmal AF. In future research, it would be of interest to
follow-up the incident AF cases overmultiple center visits to distinguish
between paroxysmal and persistent AF, and evaluate whether COPD is
associated with paroxysmal versus persistent atrial ﬁbrillation com-
pared to controls. Second, spirometric data was not available in all sub-
jects. However, asthmatic patients were excluded. Third, COPD subjects
differed from subjects without COPD in many demographic, lifestyle
and co-morbid characteristics, all of which could have an inﬂuence on
the association. Despite the fact that we evaluated the effect of almost
twenty potential confounders, still some potential confounding factors
- including valvular heart disease, hyperthyroidism and obstructive
sleep apnea - have not been taken into account. Neither has the effect
of COPD disease duration been taken into account. Covariates were
moreover adjusted for their baseline level, whereas COPD subjects
were followed since diagnosis if not present at baseline. This leaves
the possibility for residual confounding, since the confounders were
not treated time-varying. Fourth, the subgroup with available data on
IL6 was rather small, because IL6 was only measured in a 10% random
subset who received venipuncture at baseline. Nevertheless, results
from adding the IL6 data in this smaller subsample were in line with
the results from the hsCRP data, which we have measured in almost
all participants. Since CRP is an acute-phase proteinwhich increases fol-
lowing IL6 secretion, it is biologically reasonable that the AF risk associ-
ated with increased IL6 levels was higher. Therefore, IL6 might be an
interesting biomarker to predict AF risk in COPD patients, although
the shorter half-life of IL6 compared to hsCRP complicates its utility. Fi-
nally, exacerbations were measured during follow-up, implicating that
reverse causation might theoretically still be present in this analysis.
In conclusion, we observed a signiﬁcant association between COPD
and incident AF. After adjusting for the relevant confounding variables,
COPD subjects still had a 28% increased risk of developing AF. This riskonary disease and the development of atrial ﬁbrillation, Int J Cardiol
7M. Grymonprez et al. / International Journal of Cardiology xxx (xxxx) xxx–xxxwas even more pronounced in COPD subjects with frequent exacerba-
tions and with an enlarged left atrium. Importantly, this risk was driven
by COPD subjects with elevated hsCRP and IL6 plasma levels, suggesting
the important role of systemic inﬂammation in COPD on AF develop-
ment. Thismay provide new therapeutic strategies targeting underlying
systemic inﬂammation in COPD for primary and secondary prevention
of AF.
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